Implementing Early Phase Treatments for COVID-19 in Outpatient Settings: Challenges at a Tertiary Care Center in Italy and Future Outlooks

Tommaso Manciulli; Filippo Lagi; Anna Barbiero; Marco Fognani; Nicoletta Di Lauria; Costanza Malcontenti; Costanza Fiorelli; Michele Spinicci; Vega Ceccherini; Paola D'Onofrio; Manuela Angileri; Francesca Malentacchi; Michele Cecchi; Gian Maria Rossolini; Matteo Tomaiuolo; Lorenzo Zammarchi; Alessandro Bartoloni

doi:10.3390/idr14030037

Implementing Early Phase Treatments for COVID-19 in Outpatient Settings: Challenges at a Tertiary Care Center in Italy and Future Outlooks

Infect Dis Rep. 2022 Apr 25;14(3):315-320. doi: 10.3390/idr14030037.

Authors

Tommaso Manciulli¹, Filippo Lagi^{1

2}, Anna Barbiero¹, Marco Fognani¹, Nicoletta Di Lauria², Costanza Malcontenti², Costanza Fiorelli², Michele Spinicci^{1

2}, Vega Ceccherini³, Paola D'Onofrio³, Manuela Angileri⁴, Francesca Malentacchi⁵, Michele Cecchi⁴, Gian Maria Rossolini^{1

5}, Matteo Tomaiuolo³, Lorenzo Zammarchi^{1

2}, Alessandro Bartoloni^{1

2}

Affiliations

¹ Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
² Unit of Infectious and Tropical Diseases, Careggi University Hospital, 50134 Florence, Italy.
³ Hospital Management Unit, Careggi University Hospital, 50134 Florence, Italy.
⁴ Hospital Pharmacy, Careggi University Hospital, 50134 Florence, Italy.
⁵ Clinical Microbiology and Virology Unit, Careggi University Hospital, 50134 Florence, Italy.

Abstract

We present a brief commentary illustrating the current COVID-19 outpatient treatment options in Italy. We also report our experience setting up a service dedicated to these patients in the wake of the rise in COVID-19 cases observed in January 2022. We also gathered data on the daily costs faced by our outpatient service, based at a tertiary care center located in Florence, Italy. We present them with some considerations on future outlooks on the use of outpatient treatment in COVID-19.

Keywords: SARS-CoV-2; molnupiravir; monoclonal antibodies; nirmatrelvir/ritonavir; remdesivir; sotrovimab.

Grants and funding

This research received no external funding.